Terms: = Kidney tumors AND TTL, 2410003M22Rik, 150465, ENSG00000114999, MGC46235, Q8NG68 AND Treatment
2 results:
1. Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
Gandhi KA; Joshi A; Mehta P; Gurjar M; Rane P; Sharma J; Patil A; Nookala M; Noronha V; Prabhash K; Gota V
Cancer Chemother Pharmacol; 2022 Jun; 89(6):751-759. PubMed ID: 35441269
[TBL] [Abstract] [Full Text] [Related]
2. BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.
Chae JW; Teo YL; Ho HK; Lee J; Back HM; Yun HY; Karlsson MO; Kwon KI; Chan A
Cancer Chemother Pharmacol; 2016 Sep; 78(3):623-32. PubMed ID: 27485537
[TBL] [Abstract] [Full Text] [Related]
